ArticleTheranostics2019
Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Modulation of tumor-associated lymphangiogenesis by combination immunotherapy approaches in triple-negative breast cancer: a systematic review.Frontiers in immunology · 2026Pooled it
- miRNA-Based Therapeutics in Breast Cancer: A Systematic Review.Frontiers in oncology · 2021Pooled it
- Noncoding RNA as a crucial epigenetic modulator in the degeneration of the ligamentum flavum.Experimental & molecular medicine · 2024Review
- Exploring the therapeutic mechanisms of Coptidis Rhizoma in gastric precancerous lesions: a network pharmacology approach.Discover oncology · 2024Article
- Follicular fluid-derived exosomal LncRNA LIPE-AS1 modulates steroid metabolism and survival of granulosa cells leading to oocyte maturation arrest in polycystic ovary syndrome.Journal of assisted reproduction and genetics · 2024Article
- Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies.Frontiers in cell and developmental biology · 2024Review
- Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies.Stem cells international · 2024Review
- Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway.Journal of experimental & clinical cancer research : CR · 2023Article
- ER Negative Breast Cancer and miRNA: There Is More to Decipher Than What the Pathologist Can See!Biomedicines · 2023Review
- New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- Mining Potential Drug Targets for Osteoporosis Based on CeRNA Network.Orthopaedic surgery · 2023Article
- Review
- Targeting the miR-34a/LRPPRC/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer.Cell death and differentiation · 2022Article
- The functional significance and cross-talk of non-coding RNAs in triple negative and quadruple negative breast cancer.Molecular biology reports · 2022Review
- Angioregulatory microRNAs in breast cancerJournal of advanced research · 2022Review
- The lymphatic vasculature: An active and dynamic player in cancer progression.Medicinal research reviews · 2022Review
- Identification of Key Endometrial MicroRNAs and Their Target Genes Associated With Pathogenesis of Recurrent Implantation Failure by Integrated Bioinformatics Analysis.Frontiers in genetics · 2022Article
- Modulatory role of miRNAs in thyroid and breast cancer progression and insights into their therapeutic manipulation.Current research in pharmacology and drug discovery · 2022Review
- The miR-4306/IGF2R axis modulates the lung adenocarcinoma response to irradiationTranslational lung cancer research · 2021Article
- miR‑4306 inhibits the malignant behaviors of colorectal cancer by regulating lncRNA FoxD2‑AS1.Molecular medicine reports · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 4 institutions in 1 country.
Zitong ZhaoState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Lin LiBGI-Shenzhen, Shenzhen, Guangdong 518083, China.
Peina DuBGI-Shenzhen, Shenzhen, Guangdong 518083, China.
Liying MaState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Weimin ZhangLaboratory of Molecular Oncology, Peking University Cancer Hospital, Beijing 100142, China.
Leilei ZhengState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Bo LanDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Bailin ZhangDepartment of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Fei MaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Bo XuBreast Cancer Center and the Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
Qimin ZhanState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yongmei SongState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNBGI Group (China) · CNPeking University · CNPeking University Cancer Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic AgentsBiological ProductsDisease Models, AnimalDown-RegulationErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaGene Expression ProfilingGenetic TherapyHumansMiceMicroRNAsMolecular Targeted TherapyReceptors, ProgesteroneTreatment OutcomeTriple Negative Breast NeoplasmsAntineoplastic AgentsBiological ProductsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaMicroRNAsMIRN4306 microRNA, humanReceptors, ProgesteronemicroRNAtargeted therapytranscriptional regulationtriple-negative breast cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.